Tag Archives: MarketPublishers.com

World IVD Market Prospects Reviewed in New Industry Experts Report Now Available at MarketPublishers.com


London, UK (PRWEB) May 18, 2012

The global in vitro diagnostic (IVD) market is estimated to touch USD 51.2 billion and USD 53.5 billion in 2012 and 2013, respectively, with molecular diagnostics being the largest growing segment of the market.

The key factors driving the growth of the IVD market globally is increased patient awareness, patient self testing, growing baby booming population, the advancement in the technology bringing more of automated tests, as well as the rise in the number of certain diseases.

New research report ?In Vitro Diagnostics – A Global Market Overview? elaborated by Industry Experts has been recently published by Market Publishers Ltd.

Report Details:

Title: In Vitro Diagnostics – A Global Market Overview

Published: May, 2012

Pages: 493

Price: US$ 4,500.00

http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/healthcare_equipment_services/in_vitro_diagnostics_a_global_market_overview.html

The report reviews, analyzes and projects the IVD market globally and across individual regions, including North America, Europe, the Asia-Pacific, South America and ROW, with the regional markets further analyzed for 22 independent countries. The study contains statistical data for the global market by geographic region, product category and application area, and provides profiles of 47 key global players and 60 major players across the United States ? 36, Europe ? 18, and the Asia-Pacific ? 6. A global listing of 382 companies engaged in R&D, equipment manufacturing, processing, supplies and distribution of IVD products is also provided.

IVD product categories mentioned include: reagents & consumables, instruments & systems.

IVD application areas covered are: clinical chemistry, immunoassay, diabetes testing, blood testing, molecular diagnostics, pathology, cellular analysis and microbiology.

Report Contents:

Part A: Global Market Perspective

1. Introduction

1.1 Product Outline

1.1.1 Positives

1.1.2 Precision of IVDs

1.1.3 Type of Products Used For In Vitro Diagnostics

????1.1.3.1 General Purpose Reagents

????1.1.3.2 Analyte Specific Reagents

????1.1.3.3 Biochemical and Chemical Reagents: An Overview

???? 1.1.3.3.1 Opting for the Optimal Biochemical and Chemical Reagents for IVD Tests

2. A Snapshot of End-Use Applications

2.1 Clinical Chemistry

2.1.1 Clinical Chemistry Analyzers

2.2 Immunoassays

2.2.1 Objective of Immunoassays

2.2.2 Immunoassay Methodologies

2.3 Diabetes Testing

2.3.1 Primary Types of Diabetes

2.3.2 Prediabetes

2.3.3 Diagnosis of Diabetes and Prediabetes

????2.3.3.1 Fasting Plasma Glucose (FPG) Test

????2.3.3.2 Oral Glucose Tolerance Test (OGTT)

????2.3.3.3 Random Plasma Glucose Test

2.4 Blood Testing

2.4.1 Categories of Blood Tests

????2.4.1.1 Complete Blood Count (CBC)

????2.4.1.2 Red Blood Cells

????2.4.1.3 White Blood Cells

????2.4.1.4 Platelets

????2.4.1.5 Hemoglobin

????2.4.1.6 Hematocrit

????2.4.1.7 Mean Corpuscular Volume (MCV)

2.4.2 Blood Chemistry Tests/Biochemical Analysis

2.5 Molecular Diagnostics

2.5.1 Molecular Diagnostics Techniques

2.5.2 Molecular Diagnostics and Genome Research

2.5.3 Molecular Diagnostics Tools

????2.5.3.1 Sample Collection and Preparation

????2.5.3.2 Amplification and Detection Platforms and Assays

????2.5.3.3 Software Tools

????2.5.3.4 Complete Solutions

2.5.4 What the Future Holds for Molecular Tools

2.6 Pathology

2.6.1 Anatomical Pathology

2.6.2 Chemical Pathology

2.6.3 Clinical Pathology

2.6.4 Forensic Pathology

2.6.5 General Pathology

2.6.6 Genetic Pathology

2.6.7 Hematology Pathology

2.6.8 Immunopathology

2.6.9 Microbiology

2.7 Microbiology

3. Key Market Trends

Glucose Levels to be Measured via Breath with New Diabetes Device

New Technology to Protect Insulin in Africa

Depressed? Get a Blood Test

3-D Microscopy Assistance for Cell Analysis

Bacteria-Based Test Strips for Detecting Glucose Levels in Diabetics in the Offing

Mid-2012 Set Timeline for FDA for Issuing Final Guidance for In Vitro Companion Diagnostics

The 2011 Draft Guidance

Companion Diagnostic Tests

Diabetes Testing Made Easier with New Technology

In-Vitro Nanodiagnostics to Detect Pathogens: Contemporary Trends

Clinical Laboratories Offer Physicians New Diagnostic Technology for Speedier and Better Diagnosis

New Blood Test to Detect Alzheimer’s Five Years Beforehand

Early Diagnosis of Cryptococcosis Aided by New Rapid Blood Test

Diagnosis of Mesothelioma Could be Done Earlier with New Blood Test

Challenges Confronting Western Europe?s In Vitro Diagnostics Industry and Probable Solutions

Introduction

Challenges Faced by the Industry

What the Industry Needs to Accomplish

?Cry? for Measuring Blood Glucose Levels

Diabetes Care Alleviated with New Tool that Saves Time and Reduces Error Risks

Future Role of Metabolomic and Genomic Profiling in Diabetic Clinical Medicine

Introduction

Metabolomic Profiling in Clinical Medicine

Diagnosing Heart Attacks with a New Blood Test

Problems Associated with Paucity in Diagnostic Tests

Prognosis

More new market research reports by the publisher can be found at Industry Experts page.







Top Causes of Mortality Worldwide Projected to 2020 in New Espicom Study Available at MarketPublishers.com


London, UK (PRWEB) June 21, 2012

There are lots of complex reasons lying behind the shifting outlook for the cause of mortality rates worldwide. For the more developed countries, the ageing population evidently plays a prominent role, with circulatory diseases and neoplasms accounting for the majority of deaths, but as healthcare technology and lifestyle improvements start to impact related mortality, then other causes of death related to longevity become more prevalent. As far as less developed countries are concerned, healthcare technology and health information may be less obtainable. This in turn can result in increased incidence of deaths stemming from preventable or treatable diseases like circulatory disease, cancer and diabetes.

It is expected that by 2020-end, the mortality rate per 100,000 population will fall globally in such key conditions as breast cancer and respiratory diseases.

New research study ?Global Causes of Death to 2020? drawn up by Espicom Business Intelligence has been recently published by Market Publishers Ltd.

Report Details:

Title: Global Causes of Death to 2020

Published: May, 2012

Pages: 284

Price: US$ 2,265.00

http://marketpublishers.com/report/social_researches/social_studies/global_causes_of_death_to_2020.html

The research study offers an in-depth discussion of the leading causes of death throughout the world, comprising:


????analysis of trends in 23 diseases/conditions as well as forecasts of patient population growth with data covering 2012-2020;
????evaluation of the current and future patient profile by cause of death by 55 leading and emerging markets;
????assessment at global and country level;
????ranking of cause of death globally and identification of areas of increasing need;
????original forecast data.

Report Contents:

Overview

Financial Review

2011 Financial Results

Wound Care

Surgical Products

Employees

Strategic Focus

Products

Surgical Products

Wound Care Products

Research and Development

Manufacturing

Agreements

Novation

DSV

Premier

Synvasive Technology (Zimmer)

Consorta

Kuehne + Nagel

HealthTrust Purchasing Group

Broadlane/MedAssets

UPS Logistics Group

Biora

D Logistics

Innovatix

Mergers and Acquisitions

Brennen Medical

Rynel

JKT

PharmaSet

M?lnlycke Trade Mark

Thai Klinipro

Johnson & Johnson?s Barrier Brand

Divestitures

Irish Manufacturing Facility

First Aid Business

Ortman

Feminine, Consumer and Incontinence Business Units

Litigation

Brightwake

Smith & Nephew

Kinetic Concepts

Dumex Medical Surgical Products

Key Corporate Events

List of Tables

Summary Operating Results

Recent Key Events

M?lnlycke Health Care – Annual Financial Data, 2008-2011

M?lnlycke Health Care – Manufacturing Facilities

Agreements Summary

Mergers and Acquisitions Summary

M?lnlycke Health Care – Key Corporate Events

List of Charts

M?lnlycke Health Care ? Annual Sales and EBITDA, 2008-2011

M?lnlycke Health Care – Sales by Business Area, 2011

M?lnlycke Health Care – Sales by Geographic Area, 2011

More new research studies by the publisher can be found at Espicom Business Intelligence page.







Ophthalmology Therapeutics Market Reviewed in New Cutting-Edge Report Published by MarketPublishers.com


London, UK (PRWEB) October 10, 2011

The global ophthalmology market is expected to increase from last year?s USD 10.3 billion to USD 13.2 billion by 2017, growing at 3.6% CAGR. The introduction of new molecules, which are currently in the regulatory filing stage as well as in the later stages of development, will drive the market growth.

New report ?Ophthalmology Therapeutics Market to 2017 – Protein Kinase Inhibitors and Prostaglandin H-Synthase Inhibitors to Drive Diabetic Retinopathy Market? prepared by GBI Research has been recently published by Market Publishers Ltd.

Report Details:

Title: Ophthalmology Therapeutics Market to 2017 – Protein Kinase Inhibitors and Prostaglandin H-Synthase Inhibitors to Drive Diabetic Retinopathy Market

Published: October, 2011

Pages: 156

Price: US$ 3,500.00

http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/healthcare_equipment_services/ophthalmology_therapeutics_market_to_2017_protein_kinase_inhibitors_n_prostaglandin_h_synthase_inhibitors_to_drive_diabetic_retinopathy_market.html

The report provides true insights into the current and future state of the world ophthalmology therapeutics market, detailing six therapeutic indications of ophthalmology – glaucoma, allergic conjunctivitis, dry eye syndrome, diabetic macular edema, diabetic retinopathy and wet age macular degeneration. It examines global ophthalmology treatment usage patterns for the aforementioned indications and gives insights into the ophthalmology therapeutics R&D product pipeline. Furthermore, drivers and restrains, competitive landscape, key M&A activities and licensing agreements are also featured.

Report Contents:

1 TABLE OF CONTENTS

1.1 List of Tables

1.2 List of Figures

2 GLOBAL OPHTHALMOLOGY MARKET – INTRODUCTION

2.1 Overview

2.2 GBI Research Report Guidance

3 GLOBAL OPHTHALMOLOGY MARKET – MARKET CHARACTERIZATION

3.1 Introduction

3.2 Revenue Forecast for the Global Ophthalmology Market

3.2.1 Revenues

3.2.2 Annual Cost of Treatment (ACT)

3.3 Branded and Generic Market Share

3.4 Treatment Usage Patterns

3.4.1 Diseased Population

3.4.2 Treatment Seeking Population

3.4.3 Diagnosed Population

3.4.4 Prescription Population

4 GLOBAL OPHTHALMOLOGY MARKET – GEOGRAPHICAL LANDSCAPE

4.1 The US

4.1.1 Revenue

4.1.2 Annual Cost of Treatment

4.1.3 Treatment Usage Pattern

4.2 Top Five European Countries

4.2.1 Revenues of the Top Five European Countries

4.2.2 Annual Cost of Treatment

4.2.3 Treatment Usage Pattern

4.3 Japan

4.3.1 Revenues

4.3.2 Annual Cost of Treatment

4.3.3 Treatment Usage Pattern

5 GLOBAL OPHTHALMOLOGY MARKET – GLAUCOMA THERAPEUTICS MARKET

5.1 Introduction

5.2 Global Market Forecasts

5.3 Annual Cost of Treatment

5.4 Branded and Generic Market Share

5.5 Treatment Flow Algorithm

5.6 Treatment Usage Patterns

5.7 Market Forecasts for The US

5.8 Market Forecasts for the Top Five European Countries

5.9 Market Forecasts for Japan

5.10 Drivers of the Glaucoma Market

5.10.1 Increasing Prevalence of Eye Diseases

5.10.2 Improved Diagnosis of the Disease

5.11 Restraints for Glaucoma Market

5.11.1 Lower Awareness and Treatment Seeking Rates

5.11.2 Patent Expiry of Major Glaucoma Drugs such as Xalatan and Alphagan will Result in Negative Growth

6 GLOBAL OPHTHALMOLOGY MARKET – ALLERGIC CONJUNCTIVITIS

6.1 Introduction

6.1.1 Seasonal Allergic Conjunctivitis (SAC)

6.1.2 Perennial Allergic Conjunctivitis (PAC)

6.2 Market Forecasts

6.3 Annual Cost of Treatment

6.4 Branded and Generic Market Share

6.5 Treatment Flow Algorithm

6.6 Treatment Usage Patterns

6.7 Market Forecasts for the US

6.8 Market Forecasts for the Top Five European Countries

6.9 Market Forecasts for Japan

6.10 Drivers of Allergic Conjunctivitis Market

6.10.1 Increasing Awareness

6.11 Restraints for Allergic Conjunctivitis Market

6.11.1 Series of Patent Expires will Result in Slower Market Growth

7 GLOBAL OPHTHALMOLOGY MARKET – WET AGE MACULAR DEGENERATION

7.1 Introduction

7.2 Global Market Forecasts

7.3 Annual Cost of Treatment

7.4 Branded and Generic Market Share

?

Reports Examining Other Medicine, Pharmaceuticals & Biotechnology Markets are also Available:


Clinical Trial Recruitment in Dermatology – Most Trials Focus on Atopic Dermatitis While Acne Vulgaris Has Highest Patient Numbers
Biomarkers in Drug Discovery – Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly
Contraceptives Market to 2017 – Hormonal Contraceptives and Strong Pipeline to Drive the Growth in Future
HIV/AIDS Therapeutics Market to 2017 – Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries
Metabolic Disorders Therapeutics Market to 2017 – Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value

More new reports by the publisher can be found at GBI Research page.

###





More Glaucoma Press Releases

Energy Efficient Lighting Technologies Examined in New Market Research Report Published at MarketPublishers.com


London, UK (PRWEB) December 01, 2011

Recently the industry of lightning has seen substantial and important technological advancements and improvements. The fields of compact fluorescent lamps (CFL) and solid state lighting proved to be the most successful with the technology adoption. The onset of CFL and LEDs is gaining gears. LED lighting is enjoying robust growth because of its exceptional features that include high energy-efficiency, long operational life and robust weather resistant design. Lighting accounts for about 18% to 20% of total energy consumption globally. The high penetration level of CFLs and fluorescent lamps is giving the market new traits with these technologies being rather cost-competitive.

New market research study ?Global Energy Efficient Lighting Technology Market by Correlated Color Temperature (CCT), Application and Geography (2011- 2016)? prepared by Transparency Market Research has been recently published by Market Publishers Ltd.

Report Details:

Title: Global Energy Efficient Lighting Technology Market by Correlated Color Temperature (CCT), Application and Geography (2011- 2016)

Published: November, 2011

Pages: 74

Price: US$ 4,395

http://marketpublishers.com/report/industry/energy/global_energy_efficient_lighting_technology_market_by_correlated_color_temperature_cct_application_n_geography_2011_2016.html

The report offers a detailed and comprehensive insight into the today?s lightning industry and focuses on an in-depth analysis of energy-efficient lighting technologies that include Light Emitting Diode (LED), Fluorescent and Compact Fluorescent Lamp (CFL). Major products, applications, ingredients, and submarkets under each of these technologies are reviewed. The future development of the overall and sub-markets is examined through 2016.

Report Contents:

CHAPTER 1 EXECUTIVE SUMMARY

1.1 Global Energy-Efficient Lighting Market

1.2 Energy-Efficient Lighting Market By Cct (Correlated Color Temperature)

1.3 Energy-Efficient Lighting Market By Applications

1.4 Energy-Efficient Lighting Market By Geographic

CHAPTER 2 INTRODUCTION

2.1 Key Take-Aways

2.2 Scope Of The Report

2.3 Research Methodology

2.4 Stakeholders

CHAPTER 3 MARKET OVERVIEW ? LED, CFL, AND FLUORESCENT

3.1 Market Dynamics

3.2 Global Trends In The Energy Efficient Lighting Market

3.3 Consumer Preference ? Energy-Efficient Lighting Market

3.4 Lighting Usage Pattern Worldwide

3.5 Major Lighting Issues Worldwide

3.6 Competition – Energy Efficiency Scale For Energy-Efficient Lamps

3.7 Global Incandescent Demand Reduction Pattern 2004 – 2017

3.8 Cost Breakup For Lighting

3.9 Saving Potential By Switching From Incandescent To Energy-Efficient Lighting

3.10 Characteristics And Electricity Usage By Various Lamps

3.11 Cost And Performance Of Energy Efficient Lighting Source

3.12 Cfl Performance And Quality Criteria Coverage In Major Manufacturing Countries

3.13 The Influence Of Color Temperature On Mood And Lighting Applications

3.14 Case Study ? Color Temperature & Lighting For Retail Store

3.14.1 Quantity Of Light Impacts Business

3.14.2 Quality Of Light Improves Customers? Experience

3.14.3 Energy-Efficient Lighting

3.14.4 Long Operational Life, Maintenance Cost And Labor Cost

3.14.5 Benefits Of Good Lighting In Retail Stores

CHAPTER 4 LIGHT EMITTING DIODE (LED)

4.1 Market Overview

4.2 Drivers

4.2.1 Lighting Solution For Remote Areas

4.2.2 Longer Lifetime And High Energy Efficiency

4.2.3 Vibration And Thermal Shocks Resistant Solution For Better Productivity

4.2.4 Offer Scope For Various Lighting Applications

4.2.5 Harmless And Green Lighting Solution

4.3 Inhibitors & Opportunities

4.3.1 High Cost Involved

4.3.2 Lacks Attribute For Heat Sensitivity Applications

4.3.3 Unidirectional Light Output

4.3.4 Reluctance To Switch To Led Lighting

4.4 Led Market By Application

4.5 Led Market By Geography

4.6 Led Market By Color Temperature (Cct)

4.6.1 Color Temperature 2700k-3000k Market By Geography

4.6.2 Color Temperature 3500k Market By Geography

4.6.3 Color Temperature 4000k/4100k Market By Geography

4.6.4 Color Temperature 5000k-6500k Market By Geography

4.6.5 Color Temperature 6500k+ Market By Geography

CHAPTER 5 COMPACT FLUORESCENT LAMP (CFL)

5.1 Market Overview

5.2 Drivers

5.2.1 High Light Output At Low Power Consumption

5.2.2 Long Operational Life And Low Maintenance Cost

5.2.3 Payback Period

5.2.4 High Efficacy (In Comparison To Incandescent)

5.2.5 High Reliability – No Early Failures

5.2.6 Various Acceptable Size & Form

5.3 Inhibitors & Opportunities

5.3.1 Cost Barrier

5.3.2 Mercury Content In Cfl Lamps

5.4 Cfl Market By Application

5.5 Cfl Market By Geography

5.6 Cfl Market By Color Temperature (Cct)

5.6.1 Color Temperature 2700k-3000k Market By Geography

5.6.2 Color Temperature 3500k Market By Geography

5.6.3 Color Temperature 4000k/4100k Market By Geography

5.6.4 Color Temperature 5000k-6500k Market By Geography

5.6.5 Color Temperature 6500k+ Market By Geography

5.7 Cfl Programs Around The World

5.8 Cfl Performance And Quality Criteria Coverage

CHAPTER 6 FLUORESCENT

6.1 Market Overview

6.2 Drivers

6.2.1 Cost Competitive Replacement To Incandescent Bulbs

6.2.2 Energy Efficient And Long Operational Life

6.3 Inhibitors & Opportunities

6.3.1 Contains Little Amounts Of Mercury

6.3.2 Achieving Full Brightness Can Take Up To 3 Minutes

6.3.3 Suitability Issues For Outdoor Use In Cold Weather

6.4 Fluorescent Market By Application

6.5 Fluorescent Market By Geography

6.6 Fluorescent Market By Cct

6.6.1 Color Temperature 2700k-3000k Market By Geography

6.6.2 Color Temperature 3500k Market By Geography, 2010 – 2016

6.6.3 Color Temperature 4000k/4100k Market By Geography

6.6.4 Color Temperature 5000k-6500k Market By Geography

6.6.5 Color Temperature 6500k+ Market By Geography

CHAPTER 7 COMPANY PROFILE

7.1 OSRAM GMBH

7.2 ROYAL PHILIPS ELECTRONICS

7.3 NICHIA CORPORATION

7.4 GE LIGHTING

7.5 CREE, INC.

7.6 COOPER LIGHTING

7.7 BRIDGELUX INC

More new market research reports by the publisher can be found at Transparency Market Research page.

# # #







Find More Early Onset Press Releases

Psychiatry Partnering & Dealmaking Reviewed in New Research Study Recently Published at MarketPublishers.com


London, UK (PRWEB) May 09, 2012

The majority of psychiatry partnering deals in the biopharma industry are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors psychiatry technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Knowing the flexibility of a prospective partner?s negotiated deals terms provides critical insight into the negotiation process in terms of what is expected to be achieved during the negotiation of terms. While smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered.

New research study ?Psychiatry Partnering Terms and Agreements? elaborated by CurrentPartnering has been recently published by Market Publishers Ltd.

Report Details:

Title: Psychiatry Partnering Terms and Agreements

Published: March, 2012

Pages: 722

Price: US$ 2,695

http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/healthcare_equipment_services/psychiatry_partnering_terms_n_agreements.html

The report provides an enhanced understanding and access to over 1,000 psychiatry partnering deals and agreements entered into by the world?s leading healthcare companies. Top psychiatry deals by value are examined, key trends in psychiatry partnering deals are analyzed, most active psychiatry dealmakers are revealed, and listing of deals by headline value, upfront payment value, royalty rate value, stage of development at signing, deal component type, technology type, and specific therapy indication is provided within the study.

Report Contents:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Psychiatry Dealmaking

2.1. Introduction

2.2. Psychiatry partnering over the years

2.3. Bigpharma psychiatry dealmaking activity

2.4. Bigpharma not active in psychiatry

2.5. Psychiatry partnering by deal type

2.6. Psychiatry partnering by industry sector

2.7. Psychiatry partnering by stage of development

2.8. Psychiatry partnering by technology type

2.9. Psychiatry partnering by oncology indication

2.10. Average deal terms for psychiatry

2.10.1 Psychiatry headline values

2.10.2 Psychiatry upfront payments

2.10.3 Psychiatry milestone payments

2.10.4 Psychiatry royalty rates

Chapter 3 – Leading Psychiatry Deals

3.1. Introduction

3.2. Top psychiatry deals by value

3.3. Top psychiatry deals involving bigpharma

Chapter 4 – Bigpharma Psychiatry Deals

4.1. Introduction

4.2. How to use bigpharma partnering deals

4.3. Bigpharma psychiatry partnering company profiles

Abbott

Actavis

Alcon Labs

Allergan

Amgen

Apotex

Astellas

AstraZeneca

Baxter International

Bayer

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

Cephalon

Chugai

CSL

Daiichi Sankyo

Dainippon Sumitomo

Eisai

Eli Lilly

Forest Laboratories

Genzyme

Gilead Sciences

GlaxoSmithKline

Hospira

Johnson & Johnson

Kyowa Hakko Kirin

Lundbeck

Menarini

Merck & Co

Merck KGaA

Mitsubishi Tanabe

Novartis

Novo Nordisk

Nycomed Pharma

Otsuka

Pfizer

Roche

Sanofi

Servier

Shionogi

Shire

Stada

Takeda

Teva

UCB

Warner Chilcott

Watson

Chapter 5 – Dealmaking Directory

5.1. Introduction

5.2. By company A-Z

5.3. By deal type

Asset purchase

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Contract service

Co-promotion

CRADA

Development

Distribution

Evaluation

Grant

Joint venture

Licensing

Manufacturing

Marketing

Material transfer

Option

Promotion

Research

Settlement

Spin out

Supply

Technology transfer

5.4. By stage of development

Discovery

Pre-clinical

Phase I

Phase II

Phase III

Registration

Marketed

5.5. By technology type

Adjuvant

Analysis

Animal models

Assays

Biodefense

Bioinformatics

Biological compounds

Biomarkers

Biomaterials

Bioprocessing

Biosimilars/Bio-betters

Blood products

Cell culture

Cell therapy

Clinical testing

Diagnostic – companion

Devices

Diagnostics

Discovery tools

DNA probes

Drug delivery

Enabling technology

Epigenetics

Equipment

Facilities

Gene therapy

Genomics

Glycomics

Imaging

Implant

In vitro models

Microarray

Monoclonal antibodies

Nanotechnology

Natural product

Oligonucleotide

Orphan drug

Packaging

Pediatrics

Peptides

Personalised medicine

Pharmacogenomics

Processes

Proteomics

Radio/Chemo-therapy

Rational drug design

Recombinant DNA

Regenerative medicine

Research services

Research supplies

RNA therapeutics

Screening

Small molecules

Software tools

Stem cells

Toxicity

Transgenics

Vaccines

5.6. By therapeutic indication

Psychiatry

Anxiety disorder

Generalised anxiety disorder

Panic disorder

Post traumatic stress disorder

Attention deficit hyperactivity disorder

Bipolar disorder

Chronic fatigue syndrome

Cognitive impairment

Dementia

Alzheimers

Dementia with lewy bodies

Depression Autism

Mania

Obsessive compulsive disorder

Schizophrenia

Sleep disorders

More new research studies by the publisher can be found at CurrentPartnering page.







Generic & Biosimilar Opportunities with Respect to Multi-Therapy Drugs Reviewed in New Report Published by MarketPublishers.com


London, UK (PRWEB) November 01, 2011

As used here, the term multi-therapy drug refers to any drug that has either been approved for, or is in clinical development for, more than one distinct indication during its lifecycle. Multiple indications may be within an established therapy area, such as cancer, immunology or the nervous system, or they may be from different areas. Rituxan/MabThera (rituximab), for example, has been approved for both oncological and immunological conditions. Other drugs may be useful in several cancer indications or across a range of immunological or psychological conditions.

Having established their usefulness in a number of indications, many of these drugs benefit from a wide patient pool and annual sales are counted in billions of dollars. The total sales of the multi-therapy drugs exceeded USD 70 billion last year.

New report ?Multi-therapy Drugs: Opportunities for Generics & Biosimilars? developed by Espicom has been recently published by Market Publishers Ltd.

Report Details:

Title: Multi-therapy Drugs: Opportunities for Generics & Biosimilars

Published: October, 2011

Pages: 108

Price: US$ 1,740

http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/drugs_biotechnology/multi_therapy_drugs_opportunities_4_generics_biosimilars.html

The report aims to establish generic and biosimilar opportunities with respect to high-value multi-therapy drugs.

Report Contents:

FOREWORD

EXECUTIVE SUMMARY

OVERVIEW

Lifecycle Development and New Indications

Realising Additional Sales Potential

????Rituximab: Multiple Indications from Oncology to Immunology

????Sildenafil: One Active Ingredient, Two Distinctly Branded Indications

Generic and Biosimilar Opportunities

????Biosimilar Approval for Multiple Indications: Extrapolation or Additional Trials?

????US Patent Expiries

PRODUCT ANALYSIS

ANTI-METABOLITES

Alimta (pemetrexed)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

????Patents

????Generic Company Activity

????Market Outlook

Xeloda (capecitabine)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

???? Colorectal Cancer

???? Breast Cancer

???? Gastric Cancer

????Patents

????Generic Company Activity

????Market Outlook

MONOCLONAL ANTIBODIES

Rituxan/MabThera (rituximab)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

????Patents

????Biosimilar Activity

????Market Outlook

Herceptin (trastuzumab)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

???? Breast Cancer

???? Gastric Cancer

????Patents

????Biosimilar Activity

????Market Outlook

Erbitux (cetuximab)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

????Patents

????Biosimilar Activity

????Market Outlook

Avastin (bevacizumab)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

????Patents

????Biosimilar Potential

????Market Outlook

PROTEIN KINASE INHIBITORS

Glivec (imatinib)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

????Patents

????Generic Company Activity

????Market Outlook

Tarceva (erlotinib)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

????Patents

????Generic Company Activity

????Market Outlook

Sutent (sunitinib)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

????Patents

????Generic Company Activity

????Market Outlook

Nexavar (sorafenib)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

????Patents

????Generic Company Activity

????Market Outlook

OTHER ANTINEOPLASTIC AGENTS

Velcade (bortezomib)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

????Patents

????Generic Company Activity

????Market Outlook

IMMUNOSUPPRESSANTS

Enbrel (etanercept)

????Mode of Action

????Approvals

????Competition within the Marketplace

????Patents

????Biosimilar Activity

???? Merck & Co

???? Avesthagen

???? Protalix BioTherapeutics

???? Simcere

????Market Outlook

Remicade (infliximab)

????Mode of Action

????Approvals

????Competition within the Marketplace

????Patents

????Biosimilar Activity

????Market Outlook

Humira (adalimumab)

????Mode of Action

????Approvals

????Competition within the Marketplace

????Patents

????Biosimilar Activity

????Market Outlook

Cimzia (certolizumab pegol)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

????Patents

????Biosimilar Potential

????Market Outlook

Actemra (tocilizumab)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

????Biosimilar Potential

????Market Outlook

Afinitor/Zortress (everolimus)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

????Renal Cell Carcinoma

????Breast Cancer

????Patents

????Generic Company Activity

????Market Outlook

Tysabri (natalizumab)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

????Patents

????Market Outlook

NERVOUS SYSTEM

Lyrica (pregabalin)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

????Patents

????Generic Company Activity

????Market Outlook

Seroquel (quetiapine)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

????Patents

????Generic Company Activity

???? Seroquel XR

???? Seroquel IR

????Market Outlook

Abilify (aripiprazole)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

????Patents

????Generic Company Activity

????Market Outlook

Cymbalta (duloxetine)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

????Patents

????Generic Company Activity

????Market Outlook

OTHER

Viagra & Revatio (sildenafil)

????Mode of Action

????Approvals

????Lifecycle Development

????Competition within the Marketplace

????Patents

????Generic Company Activity

????Market Outlook

SOURCES

Espicom Sources

Others

DIRECTORY

Regulators

Manufacturers

INDEX

LIST OF TABLES

LIST OF FIGURES

More new research reports by the publisher can be found at Espicom page.

###







Asia Pacific Women Health Devices Market Review by iData Research Available at MarketPublishers.com


London, UK (PRWEB) April 23, 2012

The Asia-Pacific market for women?s health devices was valued at over USD 790 million in 2011. Large market potential has rendered it extremely competitive with select manufacturers leading the industry?s market share. With the elderly accounting for a large part of the overall population, thriving markets for bone densitometry, breast imaging, breast biopsy, and assisted reproduction are expected. The chances of developing osteoporosis, cancer, or infertility increases significantly with age so early screening and treatment is becoming increasingly important for aging women. In addition, the trend for both genders to conceive their first child at a later age than in the past is further increasing growth within these markets. Technological advancements and production innovations in markets like breast imaging, assisted reproduction, and OB/GYN ultrasound have led to extremely high growth in certain segments.

New research report ?Asia Pacific Markets for Women?s Health Devices 2012? provided by iData Research has been recently published by Market Publishers Ltd.

Report Details:

Title: Asia Pacific Markets for Women?s Health Devices 2012

Published: April, 2012

Pages: 596

Price: US$ 8,495

http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/healthcare_equipment_services/asia_pacific_markets_4_womens_health_devices_2012.html

The research report provides a comprehensive and detailed analysis of the Asia-Pacific market for women?s health devices. It features revenues by device type, market forecasts through 2018, unit sales, average selling prices, market driving and limiting forces, and an elaborate competitive analysis including manufacturer market shares and product portfolios.

Countries covered in the report include: South Korea, Japan, and Australia.

Report Contents:

List of Figures

List of Charts

Executive Summary

1.1 Total Asia-Pacific Women?s Health Market

1.2 Country Profile (Optional)

1.3 Growth Trends By Segment

1.4 Procedure Numbers

1.5 Competitive Analysis

Research Methodology

2.1 Research Scope

2.2 iData?s 9-Step Methodology

2.2.1 Step 1: Project Initiation & Team Selection

2.2.2 Step 2: Prepare Data Systems and Perform Secondary Research

2.2.3 Step 3: Preparation for Interviews & Questionnaire Design

2.2.4 Step 4: Performing Primary Research

2.2.5 Step 5: Research Analysis: Establishing Baseline Estimates

2.2.6 Step 6: Market Forecast and Analysis

2.2.7 Step 7: Identify Strategic Opportunities

2.2.8 Step 8: Final Review and Market Release

2.2.9 Step 9: Customer Feedback and Market Monitoring

Asia-Pacific Women?s Health Market

3.1 Introduction

3.1.1 Diseases and Conditions Treated By the Products in this Report

3.1.2 Products Covered in the Report

3.1.3 Introduction to the countries covered in this report.

3.2 Currency Exchange Rates

3.3 MARKET BY OVERVIEW

3.3.1 Market by Segment

3.3.2 Market by Country

3.4 TREND ANALYSIS

3.4.1 By Segment

3.4.2 By Country

3.5 Market Drivers and Limiters

3.5.1 Market Drivers

3.5.2 Market Limiters

3.6 Competitive Analysis

3.6.1 Leading Competitors

3.6.2 Market Concentration

3.7 Mergers and Acquisitions

Country Profiles

4.1 Introduction

4.1.1 Population

4.1.2 GDP per Capita

4.1.3 Price Index

4.1.4 Other Metrics

4.2 Japan

4.3 South Korea

4.4 Australia

Procedure Numbers

5.1Women?s Health Procedure Numbers

5.1.1 Mammography Procedures

5.1.2 Breast Biopsy Procedures

5.1.3 Artificial Reproduction Therapy Procedures

Japan

6.1 Introduction

6.2 Procedures

Overview of the Women?s Health Market

7.1 Introduction

7.2 Currency Exchange Rates

7.3 Market Analysis

7.3.1 Overall Market

7.3.2 Women?s Health Market Value by Segment

7.4 Trend Analysis by Market Segment

7.5 Market Drivers and Limiters

7.5.1 Market Drivers

7.5.2 Market Limiters

7.6 Competitive Analysis

7.7 Mergers and Acquisitions

Japanese Bone Densitometry Market

8.1 Introduction

8.2 Market Overview

8.3 Market Forecast and Analysis

8.3.1 Central DEXA Market

8.3.2 Peripheral DEXA Market

8.3.3 Quantitative Ultrasonometry (QUS) Market

8.4 Market Drivers and Limiters

More new market reports by the publisher can be found at iData Research page.







Cefixime Examined in New Patent Search Report by Genericsweb Published at MarketPublishers.com


London, UK (PRWEB) January 30, 2012

Cefixime is a semi-synthetic (partially man-made), oral antibiotic in the cephalosporin family of antibiotics. The cephalosporin family includes cephalexin (Keflex), cefaclor (Ceclor), efuroxime (Zinacef), cefpodoxime (Vantin), cefprozil (Cefzil), and many injectable forms. Like other cephalosporins, cefixime stops bacteria from multiplying by preventing bacteria from forming the walls that surround them.

Cefixime is effective for infections of the middle ear (otitis media), tonsillitis, throat infections (pharyngitis), laryngitis, bronchitis, and pneumonia caused by susceptible bacteria. It also is used for treating urinary tract infections and gonorrhea as well as acute bacterial bronchitis in patients with chronic obstructive pulmonary disease (COPD).

New report ?Cefixime – Comprehensive patent search? worked out by Genericsweb has been recently published by Market Publishers Ltd.

Report Details:

Title: Cefixime – Comprehensive patent search

Published: January 25, 2012

Price: US$ 7,200

http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/drugs_biotechnology/cefixime_comprehensive_patent_search.html

The pipeline developer report on Cefixime is a regularly updated, professional patent search, which not only identifies relevant patents, but presents categorization and interpretation, all delivered by a convenient online interface.

Pipeline Developer Report Features:


????comprehensive patent searching, offering data for the world’s key territories;
????patents covering molecule, formulation, process, use, combination and assay techniques;
????patent identification, categorization and interpretation;
????grouping by patent family, interpretation of key aspects of the patent claims;
????filtration of patents not relevant to generic development;
????relevant changes to patent families, statuses, and litigation;
????hyper-linking to crucial patent documents and national registers.

Patent Categories Identified Include:

????molecular form;
????active ingredient preparation;
????formulations & methods thereof;
????related medical use & administration;
????active ingredient combinations;
????analytical methods.

More new pipeline reports by the publisher can be found at Genericsweb page.

###





Related Otitis Media Press Releases

Powered by WordPress | Designed by: best suv | Thanks to toyota suv, infiniti suv and lexus suv